← Eichor
Condition: Sjogren Syndrome Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Sjogren Syndrome

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease
Phase 2 · 1 location(s) · National Institute of Dental and Craniofacial Research (NIDC · NCT07281456Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
Phase 1/Phase 2 · 1 location(s) · Peking University Third Hospital · NCT06828042Home Based Clinical Management of Interstitial Lung Disease in Systemic Rheumatic Diseases
NA · 1 location(s) · Oslo University Hospital · NCT06732674Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.
Phase 1/Phase 2 · 1 location(s) · Beijing GoBroad Hospital · NCT06947473A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT06978647Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
NA · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06614270Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Diseas
Phase N/A · 1 location(s) · Hospital Universitario Araba · NCT07249060Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
Phase N/A · 1 location(s) · Brain Inflammation Collaborative · NCT04806620Clinical Cohort Study in Patients With Different Subtypes of Primary Sjogren Syndrome Related Dry Eye
Phase N/A · 1 location(s) · Peking University Third Hospital · NCT05605314AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Stud
Phase 2 · 52 location(s) · Artiva Biotherapeutics, Inc. · NCT06991114A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
Phase 1 · 11 location(s) · Cullinan Therapeutics Inc. · NCT07041099Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic D
Phase 2 · 121 location(s) · Immunovant Sciences GmbH · NCT06979531Evaluating a New Therapy for Dry Eye in Patients With Sjögren's Syndrome
Phase 4 · 1 location(s) · Center For Sight · NCT07277257TREATMENT OF VAGINAL DRYNESS IN SJÖGREN'S DISEASE WITH CO2-LASER VERSUS TOPICAL PROMESTRIENE
Phase 4 · 1 location(s) · University of Sao Paulo General Hospital · NCT07153276Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Phase N/A · 2 location(s) · Sanford Health · NCT01793168Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT07184450Medico-economic and Quality of Life Impact of Sjogren-associated Small Fiber Neuropathy
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT03509064Rare AutoImmune SElf-management Programme Development
Phase N/A · 1 location(s) · University of the West of England · NCT06642870The Myelin Disorders Biorepository Project
Phase N/A · 23 location(s) · Children's Hospital of Philadelphia · NCT03047369A Study of OL-CD19-GDT in Relapsed/ Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Beijing GoBroad Hospital · NCT07167537CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
Phase 1/Phase 2 · 1 location(s) · Beijing GoBroad Hospital · NCT06947460A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT07123519Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NI
Phase 1 · 52 location(s) · National Cancer Institute (NCI) · NCT03816345BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
Phase 2 · 1 location(s) · Peking University People's Hospital · NCT06794008Fatigue in Sjögren's Syndrome: 3 Therapeutic Strategies
NA · 1 location(s) · Centre Hospitalier Universitaire de Saint Etienne · NCT06875102
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.